Allogene Therapeutics Inc (ALLO)
2.96
+0.04
(+1.54%)
USD |
NASDAQ |
May 02, 16:00
2.96
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Cash from Investing (Quarterly): 67.46M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 67.46M |
| September 30, 2023 | -34.27M |
| June 30, 2023 | 17.16M |
| March 31, 2023 | 112.94M |
| December 31, 2022 | 49.60M |
| September 30, 2022 | 24.90M |
| June 30, 2022 | 54.03M |
| March 31, 2022 | -22.38M |
| December 31, 2021 | 29.25M |
| September 30, 2021 | 13.01M |
| June 30, 2021 | 24.59M |
| March 31, 2021 | 96.80M |
| Date | Value |
|---|---|
| December 31, 2020 | 22.21M |
| September 30, 2020 | -83.36M |
| June 30, 2020 | -428.97M |
| March 31, 2020 | -15.01M |
| December 31, 2019 | 7.929M |
| September 30, 2019 | 78.78M |
| June 30, 2019 | 44.49M |
| March 31, 2019 | 32.89M |
| December 31, 2018 | -313.39M |
| September 30, 2018 | -316.78M |
| June 30, 2018 | -2.634M |
| March 31, 2018 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-428.97M
Minimum
Jun 2020
112.94M
Maximum
Mar 2023
3.114M
Average
24.59M
Median
Jun 2021
Cash from Investing (Quarterly) Benchmarks
| Agenus Inc | 2.824M |
| ANI Pharmaceuticals Inc | -4.779M |
| Vaxart Inc | 15.10M |
| aTyr Pharma Inc | 17.82M |
| PAVmed Inc | -0.183M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -53.71M |
| Cash from Financing (Quarterly) | 0.155M |
| Free Cash Flow | -239.25M |
| Free Cash Flow Per Share (Quarterly) | -0.3199 |
| Free Cash Flow to Equity (Quarterly) | -53.89M |
| Free Cash Flow Yield | -51.53% |